← Leaderboards
Wenzhe Ho
Children'S Hospital Of Philadelphia
$18,646,932
Attributed
$22,699,526
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,699,526 · 14
By mechanism
R01$19,976,831 · 8
R21$1,943,732 · 5
P01$778,963 · 1
Top collaborators
- Wenhui Hu5 shared
- Allison Michelle Andrews3 shared
- Raghava Potula3 shared
- Jian Zhu3 shared
Most similar at Children'S Hospital Of Philadelphia
Same institution · by research overlap
- Steven Daniel Douglas$42,176,966
- John H Wolfe$36,931,901
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsCellsMacrophageIn VitroMediatingMorphineOpioidNatural ImmunityNeuronsMonocyteBaseInfectionMicrogliaIn VivoAstrocytesCd4 Positive T LymphocytesVirusPlasmaPredispositionDrug AbuseCofactorImpairmentImmuneVirus Diseases
Grant awards (76)
Synthetic fentanyls adversely affect the blood-brain barrier and HIV replication in the context of neuroHIV$687,535
R01 · FY2025 · DA
Target Host Epigenetic Regulation of HIV Proviruses to Reinforce Viral Deep Latency in Microglia$679,675
R01 · FY2025 · MH
Synthetic fentanyls adversely affect the blood-brain barrier and HIV replication in the context of neuroHIV$726,849
R01 · FY2024 · DA
Target Host Epigenetic Regulation of HIV Proviruses to Reinforce Viral Deep Latency in Microglia$688,355
R01 · FY2024 · MH
HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral Organoids$617,622
R01 · FY2024 · DA · contact PI
Target Host Epigenetic Regulation of HIV Proviruses to Reinforce Viral Deep Latency in Microglia$788,697
R01 · FY2023 · MH
Synthetic fentanyls adversely affect the blood-brain barrier and HIV replication in the context of neuroHIV$730,880
R01 · FY2023 · DA
HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral Organoids$617,622
R01 · FY2023 · DA · contact PI
HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral Organoids$617,622
R01 · FY2022 · DA · contact PI
Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation$396,250
R01 · FY2022 · DA · contact PI
HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral Organoids$617,622
R01 · FY2021 · DA · contact PI
Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation$396,250
R01 · FY2021 · DA · contact PI
Effect of Methamphetamine and/or HIV on Human iPSCs-derived microglia and Neuron$198,125
R21 · FY2021 · DA · contact PI
HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral Organoids$617,622
R01 · FY2020 · DA · contact PI
Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation$396,250
R01 · FY2020 · DA · contact PI
Methamphetamine, Innate Immunity and HIV$351,000
R01 · FY2020 · DA · contact PI
Effect of Methamphetamine and/or HIV on Human iPSCs-derived microglia and Neuron$237,750
R21 · FY2020 · DA · contact PI
Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation$396,250
R01 · FY2019 · DA · contact PI
Methamphetamine, Innate Immunity and HIV$351,000
R01 · FY2019 · DA · contact PI
Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation$396,250
R01 · FY2018 · DA · contact PI
Methamphetamine, Innate Immunity and HIV$351,000
R01 · FY2018 · DA · contact PI
Opioids, Extracellular Vesicles and BBB Innate Immunity$198,125
R21 · FY2018 · DA · contact PI
Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation$10,087
R01 · FY2018 · DA · contact PI
Methamphetamine, Innate Immunity and HIV$351,000
R01 · FY2017 · DA · contact PI
Opioids, HIV/HCV and host cell innate immunity$271,250
R01 · FY2017 · DA · contact PI
Opioids, Extracellular Vesicles and BBB Innate Immunity$237,750
R21 · FY2017 · DA · contact PI
Methamphetamine, Innate Immunity and HIV$351,000
R01 · FY2016 · DA · contact PI
Opioids, HIV/HCV and host cell innate immunity$235,966
R01 · FY2016 · DA · contact PI
Opioids, HIV/HCV and host cell innate immunity$234,774
R01 · FY2015 · DA · contact PI
Opioids, HIV/HCV and host cell innate immunity$5,076
R01 · FY2015 · DA · contact PI
Opioids, LPS and HIV$258,035
R01 · FY2014 · DA · contact PI
Opioids, HIV/HCV and host cell innate immunity$238,350
R01 · FY2014 · DA · contact PI
Opioid, Astroglial TLR3/RIG-I Signaling and HIV$193,750
R21 · FY2014 · DA · contact PI
Opioids, LPS and HIV$5,940
R01 · FY2014 · DA · contact PI
Drug Abuse, Sustance P and HIV$318,832
R01 · FY2013 · DA · contact PI
Opioids, HIV/HCV and host cell innate immunity$247,975
R01 · FY2013 · DA · contact PI
Opioids, LPS and HIV$247,714
R01 · FY2013 · DA · contact PI
Opioid, Astroglial TLR3/RIG-I Signaling and HIV$232,500
R21 · FY2013 · DA · contact PI
Drug Abuse, Sustance P and HIV$331,721
R01 · FY2012 · DA · contact PI
Opioids, LPS and HIV$299,350
R01 · FY2012 · DA · contact PI
Drug Abuse, Sustance P and HIV$330,825
R01 · FY2011 · DA · contact PI
Opioids, LPS and HIV$299,350
R01 · FY2011 · DA · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$287,975
R01 · FY2011 · DA · contact PI
Drug Abuse, Sustance P and HIV$351,312
R01 · FY2010 · DA · contact PI
Opioids, LPS and HIV$318,600
R01 · FY2010 · DA · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$294,941
R01 · FY2010 · DA · contact PI
Drug Abuse, Sustance P and HIV$383,637
R01 · FY2009 · DA · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$222,484
R01 · FY2009 · DA · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$81,639
R01 · FY2009 · DA · contact PI
Drug Abuse, Sustance P and HIV$14,008
R01 · FY2009 · DA · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$7,020
R01 · FY2009 · DA · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$402,864
R01 · FY2008 · DA · contact PI
Drug Abuse, Substance P and HIV$308,499
R01 · FY2008 · DA · contact PI
Neurokinin-1R Antagonists- Anti-HIV Mechanisms$187,601
P01 · FY2008 · MH · contact PI
Methamphetamine and HIV Infection$69,395
R21 · FY2008 · DA · contact PI
Methamphetamine and HIV Infection$66,337
R21 · FY2008 · DA · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$7,020
R01 · FY2008 · DA · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$330,000
R01 · FY2007 · DA · contact PI
Drug Abuse, Substance P and HIV$287,443
R01 · FY2007 · DA · contact PI
Neurokinin-1R Antagonists- Anti-HIV Mechanisms$210,526
P01 · FY2007 · MH · contact PI
Opioids, HIV/HCV and Host Cell Innate Immunity$82,293
R01 · FY2007 · DA · contact PI
Drug Abuse, Substance P and HIV$326,872
R01 · FY2006 · DA · contact PI
Neurokinin-1R Antagonists- Anti-HIV Mechanisms$193,186
P01 · FY2006 · MH · contact PI
Drug Abuse, Substance P and HIV$21,600
R01 · FY2006 · DA · contact PI
Drug Abuse, Substance P and HIV$362,562
R01 · FY2005 · DA
Neurokinin-1R Antagonists- Anti-HIV Mechanisms$187,650
P01 · FY2005 · MH
Drug Abuse, Substance P and HIV$316,083
R01 · FY2004 · DA
HCV, HIV and Opioids: Cellular Interactions$170,000
R21 · FY2004 · DA
Drug Abuse, Substance P and HIV$36,870
R01 · FY2004 · DA
DRUG ABUSE, SUBSTANCE P AND HIV$335,432
R01 · FY2003 · DA
HCV, HIV and Opioids: Cellular Interactions$170,000
R21 · FY2003 · DA
DRUG ABUSE, SUBSTANCE P AND HIV$251,656
R01 · FY2002 · DA
HCV, HIV and Opioids: Cellular Interactions$170,000
R21 · FY2002 · DA
DRUG ABUSE, SUBSTANCE P AND HIV$26,787
R01 · FY2002 · DA
DRUG ABUSE, SUBSTANCE P AND HIV$263,901
R01 · FY2001 · DA
DRUG ABUSE, SUBSTANCE P AND HIV$193,737
R01 · FY2000 · DA